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Abstract
Background: Tumor hypoxia is marked by enhanced expression of hypoxia-inducible factor-α (HIF-1α) and glucose 
transporter-1 (Glut-1). Hypoxic conditions have also been associated with overexpression of angiogenic factors, such as 
leptin. The aim of our study was to analyze the relationships between hypoxia markers HIF-1α, Glut-1, leptin, leptin 
receptor (ObR) and other breast cancer biomarkers in primary and metastatic breast cancer in patients treated or 
untreated with preoperative chemotherapy.
Methods: The expression of different biomarkers was examined by immunohistochemistry in 116 primary breast 
cancers and 65 lymph node metastases. Forty five of these samples were obtained form patients who received 
preoperative chemotherapy and 71 from untreated patients.
Results: In primary tumors without preoperative chemotherapy, HIF-1α and Glut-1 were positively correlated (p = 0.02, 
r = 0.437). HIF-1α in primary and metastatic tumors without preoperative therapy positively correlated with leptin (p < 
0.0001, r = 0.532; p = 0.013, r = 0.533, respectively) and ObR (p = 0.002, r = 0.319; p = 0.083, r = 0.387, respectively). 
Hypoxia markers HIF-1α and Glut-1 were negatively associated with estrogen receptor alpha (ERα) and positively 
correlated with estrogen receptor beta (ERβ). In this group of tumors, a positive correlation between Glut-1 and 
proliferation marker Ki-67 (p = 0.017, r = 0.433) was noted. The associations between HIF-1α and Glut-1, HIF-1α and 
leptin, HIF-1α and ERα as well as Glut-1 and ERβ were lost following preoperative chemotherapy.
Conclusions: Intratumoral hypoxia in breast cancer is marked by coordinated expression of such markers as HIF-1α, 
Glut-1, leptin and ObR. The relationships among these proteins can be altered by preoperative chemotherapy.
Background
During breast cancer development and progression, rap-
idly proliferating neoplastic cells are often exposed to
hypoxia resulting from insufficient local supply of oxygen
and nutrition [1]. Hypoxia can affect developing tumor
two-way. On one hand, it might inhibit proliferation and
stimulate apoptotic or necrotic cell death, while it can
also induce progression of neoplasms and cause resis-
tance to anti-cancer treatments. In developing tumors,
hypoxic cells are more resistant to ionizing radiation and
chemotherapy, display a more invasive and metastatic
phenotype, and increased genetic instability. Limited oxy-
gen concentration in tumor tissue is known to modulate
(inhibit or stimulate) gene expression as well as affect
metabolic processes [2-5].
Hypoxia-inducible factor-1 (HIF-1) and glucose trans-
porter-1 (Glut-1) are two known markers of tissue oxy-
genation. HIF-1 is heterodimeric transcription factor that
consists of a constitutively expressed HIF-1β subunit and
a hypoxia-induced HIF-1α subunit [6,7]. Under normoxic
conditions, HIF-1α is rapidly degraded, but hypoxia or
activation of certain intracellular pathways, such as the
PI-3K and ERK1/2 pathways, induce accumulation of this
protein and its translocation to the nucleus. Additionally,
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tumor suppressor genes PTEN and p53 [7,8]. HIF-1α
binds to Hypoxia Response Elements (HRE, 5'-RCGTG-
3') within regulatory regions of target genes whose pro-
tein products are implicated in metabolism, growth,
angiogenesis and apoptosis [9-11]. Expression of HIF-1α
is characteristic of early stages of carcinogenesis and has
been correlated with increased intratumoral angiogene-
sis, cancer progression, poor patient prognosis and
chemo- as well as radio- resistance [12-14].
Glucose transporter-1 (Glut-1) is another protein
whose expression in tumor is hypoxia-dependent [15-17].
Glut-1 exerts cytoprotective effect enabling glucose
transport into hypoxic cells, and preventing hypoxia-
induced cell death. Glut-1 accumulation was observed in
cancer cells in regions near necrotic areas in tumors [18].
Under hypoxic conditions, Glut-1 expression can be
enhanced by HIF-1α [19]. Hayashi et al. (2004) found that
this phenomenon involves HIF-1α interaction with a
HRE site in the Glut-1 promoter [20].
In breast cancer, increased expression of Glut-1 was
associated with higher invasiveness of breast cancer cell
lines and with the poorly differentiated phenotype in
human ductal mammary cancers [21]. Glut-1 overexpres-
sion in colorectal cancer cells was associated with rapid
cancer progression and inversely correlated with progno-
sis [22]. In breast and lung cancer cell models, blocking of
Glut-1 with specific antibodies reduced growth and
induced apoptosis [23]. We found significant coexpres-
sion of Glut-1, and apoptotic regulators Bcl-xL and Bax in
colorectal cancer, which could suggest cooperation
among these proteins in processes such as elimination of
cells due to irreversible injury, adaptation to hypoxia,
reduction of further damage, and survival [16].
Hypoxia can also upregulate the expression of a
cytokine leptin (Ob) - a multifunctional peptide hormone
that has been implicated in cancer cell growth, transfor-
mation, metastasis and resistance to cancer treatments
[24-33]. Our recent study indicated that leptin and the
leptin receptor (ObR) were significantly overexpressed in
primary breast cancer and lymph node metastasis relative
to non-cancer mammary epithelium [34]. The leptin gene
promoter contains eight HRE with the minimal core
sequence 5'-RCGTG-3' that can recruit HIF-1α [35].
R e c e n t l y ,  w e  d e m o n s t r a t e d  t h a t  i n  b r e a s t  c a n c e r  c e l l s ,
leptin and ObR expression can be activated in response to
hypoxia or hyperinsulinemia [34,36]. In the case of leptin
expression, the process was mediated through HIF-1 and/
or Sp-1-dependent transcription [37,38].
Here we analyzed the relationships between hypoxia-
related proteins (HIF-1α, Glut-1, leptin, ObR) and other
cancer biomarkers in primary breast cancer and lymph
node metastases. We also assessed the impact of preoper-
ative chemotherapy (neoadjuvant therapy) on the correla-
tive expression of these proteins.
Methods
Patients and tissue samples
The expression of HIF-1α, Glut-1, leptin, ObR, estrogen
receptors ERα, ERβ and Ki-67 was assessed in breast can-
cer samples obtained from 116 women, aged 30-82 years
(mean age 54.4), who underwent partial or total mastec-
tomy and lymph node dissection for primary breast can-
cer. Forty five patients from this group underwent
preoperative chemotherapy (neoadjuvant therapy) fol-
lowing Ansfield (cyclophosphamid, prednison, 5-fluorou-
racyl, metotrexate and vincristin) or CMF
(cyclophosphamid, metotrexat, 5-fluorouracyl) regimens.
As the aim of the present study was not the evaluation of
the impact of a particular preoperative chemotherapy
regimen, all the Ansfiled and CMF patients were analyzed
as one group.
Tissue samples were fixed in 10% buffered formalde-
hyde solution, embedded in paraffin blocks at 56°C and
stained with hematoxylin-eosin. Histopathological exam-
ination of sections was based on the WHO and pTN clas-
sification of breast tumors [39]. These human studies
were performed in agreement with the ethical standards
laid down in the 1964 Declaration of Helsinki and its lat-
est revision in 2000, and approved by the Ethics Commit-
tee at Medical University of Bialystok. All subjects signed
informed consent before inclusion in the study. In order
to uniform the examined group without neoadjuvant
therapy, the analysis included selected cases of invasive
ductal carcinomas in grade G2 (49 patients without pre-
operative chemotherapy) and G3 (22 patients without
preoperative chemotherapy) and in stage pT1 (43 patients
without preoperative chemotherapy) and pT2 (28
patients without preoperative chemotherapy). Tumor
stage and grade were impossible to determine in the
group of tumors after chemotherapy because of numer-
ous morphological changes in epithelial and stromal tis-
sue components. The presence of lymph node metastases
was found at the time of diagnosis in 35 patients (49.3%)
who did not receive preoperative chemotherapy and in 30
patients (66.7%) who underwent preoperative chemo-
therapy.
Immunohistochemistry
The immunohistochemical analysis of HIF-1α, Glut-1,
leptin (Ob), ObR, ERα, ERβ, and Ki-67 expression was
carried out using 5 μm consecutive tissue sections
obtained from tissue samples, as described by us previ-
ously in detail [16,28-30,34,40]. The sections were dew-
axed in xylene and rehydrated in graded alcohols. After
antigen unmasking and endogenous peroxidase removal,
nonspecific binding was blocked by incubating the slides
for 1 h with 1.5% normal serum in PBS. Next, the sections
were incubated with the primary antibodies (Abs). The
following Abs were used for marker detection: for HIF-Koda et al. BMC Cancer 2010, 10:320
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1α, rabbit polyclonal Ab (sc-10790; Santa Cruz Biotech-
nology, Santa Cruz, USA), dilution 1:400; for Glut-1, rab-
bit polyclonal Ab (A3536; Dako, Denmark), dilution
1:250; for leptin, rabbit polyclonal Ab (pAb) A-20 (Santa
Cruz, USA), dilution 1:100; for ObR, rabbit pAb H-300
(Santa Cruz, USA), dilution 1:75; for ERα, mouse mono-
clonal Ab (mAb) F-10 (Santa Cruz, USA), dilution 1:200;
for ERβ, rabbit pAb H-150 (Santa Cruz, USA), dilution
1:200; and for Ki-67, mouse mAb MIB-1 (Dako, Den-
mark), dilution 1:100. The analysis of leptin, ObR, ERα
and ERβ was performed with avidin-biotin-peroxidase
complex (ABC Staining System, Santa Cruz, USA), for
HIF-1α and Glut-1 with EnVision method (Dako, Den-
mark), and for Ki-67 with streptavidin-biotin-peroxidase
complex (LSAB kit, Dako, Denmark) to reveal Ab-antigen
reactions. All slides were counterstained with hematoxy-
lin. Breast specimens previously classified as positive for
the expression of the studied markers were used for con-
trol and protocol standardization. In negative controls,
primary Abs were omitted. The expression of leptin,
ObR, ERα, ERβ, and Ki-67 was analyzed by light micros-
copy in 10 different section fields, and the mean percent-
age of tumor cells displaying positive staining was scored.
The expression of leptin and ObR in cancer samples was
classified using a four-point scale: 0, <10% positive cells;
1+, 10-50% positive cells with weak staining; 2+, >50%
positive cells with weak staining; 3+, >50% positive cells
with strong staining. ERα and ERβ were classified as fol-
lows: 0, <10% cells with positive staining; 1+, 10-50% cells
with positive staining; 2+, 50-80% cells with positive
staining; 3+ >80% cells with positive staining. Ki-67
expression was classified as follows: 0, <10% cells with
positive staining; 1+, 10-40% cells with positive staining;
2+ >40% cells with positive staining. For HIF-1α and
Glut-1, we applied a 3-grade scoring system as follows: 0,
<10% immunoreactive cancer cells; 1+, 10-50% immuno-
reactive cancer cells; 2+, >50% of immunoreactive malig-
nant cells.
Statistical analysis
Spearman test was used to analyze correlations among
leptin, ObR, HIF-1α, Glut-1, ERα, ERβ, and Ki-67 expres-
sion in primary and metastatic breast cancer in the group
with and without preoperative chemotherapy. Values of p
< 0.05 were taken as statistically significant.
Results
The positivity scores for HIF-1α, Glut-1, leptin, ObR,
ERα, ERβ and Ki-67 in primary and metastatic breast
cancer in the group without and with preoperative che-
motherapy are included in Table 1 and 2. We found a sig-
nificant correlation between HIF-1α and leptin
expression in primary tumors and lymph node metasta-
ses in patients who did not receive preoperative chemo-
therapy (Table 3 and 4). This relationship was not
observed in breast tumors of patients who received neo-
adjuvant therapy. On the other hand, the expression of
HIF-1α was correlated with the presence of ObR in pri-
mary breast cancer regardless of preoperative treatment
(Table 3 and 4). In lymph node metastases from women
without neoadjuvant therapy, a trend toward a positive
correlation between HIF-1α and ObR was detected
(Table 4). However, in lymph node metastases from
patients after neodjuvant therapy, HIF-1α and ObR were
not associated (Table 4).
Glut-1 did not correlate with leptin or ObR in any stud-
ied group of breast tumors (Table 3 and 4). On the other
hand, a positive correlation between HIF-1α and Glut-1
was found in primary tumors, but not in lymph node
metastasis in patients without preoperative chemother-
apy (Table 3). The association between HIF-1α and Glut-
1 was not observed in primary or metastatic cancers in
patients who received neoadjuvant therapy (Table 3 and
4).
Next, we studied relationships between hypoxia mark-
ers and estrogen receptor expression. In primary tumors
without preoperative chemotherapy, we noted a trend
toward a negative correlation between HIF-1α expression
and ERα (p = 0.055, r= -0.194; Table 3). These associa-
tions were absent in lymph node metastases. HIF-1α and
ERα did not correlate in primary tumors and metastases
from patients who underwent preoperative chemother-
apy (Table 3 and 4).
Glut-1 negatively correlated with ERα expression in pri-
mary tumors and in lymph node metastases in biopsies
from all patients, regardless of preoperative treatment
(Table 3 and 4). ERβ positively correlated with HIF-1α in
primary tumors, both in patients with and without pre-
operative chemotherapy (Table 3), and with Glut-1 in pri-
mary tumors without preoperative chemotherapy (Table
3).
Finally, we evaluated the link between HIF-1α, Glut-1
and the proliferation marker Ki-67. A positive correlation
between Glut-1 and Ki-67 was noted in primary and met-
astatic cancer biopsies from patients without preopera-
tive chemotherapy (Table 3, 4). In the group of primary
tumors after neodjuvant therapy, we observed a trend
toward a positive correlation in primary tumors only
(Table 3). On the other hand, HIF-1α did not correlate
with Ki-67 in primary tumors or in lymph node metasta-
ses in both studied groups of patients (Table 3 and 4).
Discussion
In this study we analyzed the relationships among
hypoxia-inducible proteins (i.e., HIF-1α, Glut-1, leptin,
and ObR) and other biomarkers (i.e., estrogen receptors
and Ki-67) in primary and metastatic breast cancer. Our
second goal was to evaluate potential influence of preop-Koda et al. BMC Cancer 2010, 10:320
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erative chemotherapy on associations among studied
proteins. The major findings of our study can be summa-
rized as follows: 1) HIF-1α and Glut-1 are positively cor-
related in primary tumors without preoperative
chemotherapy; 2) HIF-1α positively correlate with the
leptin system in primary and metastatic breast cancer
without preoperative chemotherapy; 3) the leptin system
is not associated with Glut-1 expression in all studied
groups; 4) Glut-1 correlates negatively with ERα in pri-
mary and metastatic tumors, regardless of preoperative
chemotherapy; 5) hypoxia markers correlate positively
with ERβ expression in primary tumors, especially in the
group without preoperative therapy; 6) Glut-1 expression
is positively associated with Ki-67 in primary tumors,
while in lymph node metastases, a trend toward positive
correlation between these proteins is found in the group
Table 1: Positivity scores for different biomarkers in primary tumors and lymph node metastases in patients without preoperative 
chemotherapy.
Biomarkers Primary tumors; n = 71 Lymph node metastases; n = 35
0 1+ 2+ 3+ 0 1+ 2+ 3+
HIF-1α 27 21 23 - 11 9 15 -
GLUT-1 38 21 12 - 24 5 6 -
Ob 10 24 28 9 3 6 15 11
ObR 44 16 7 4 17 7 8 3
ERα 21 11 27 12 11 8 7 9
ERβ 10 22 27 12 5 10 9 11
Ki-67 20 29 22 - 9 18 8 -
n - number of studied cases.
Table 2: Positivity scores for different biomarkers in primary tumors and lymph node metastases in patients after preoperative 
chemotherapy.
Biomarkers Primary tumors; n = 45 Lymph node metastases; n = 30
0 1+ 2+ 3+ 0 1+ 2+ 3+
HIF-1α 10 24 11 - 5 13 12 -
GLUT-1 24 16 5 - 15 11 4 -
Ob 91 51 83 4 9 1 4 3
ObR 29 11 5 0 12 6 8 4
ERα 17 10 11 7 10 6 6 8
ERβ 992 34 5 5 1 3 7
Ki-67 17 20 8 - 11 13 6 -
n - number of studied cases.Koda et al. BMC Cancer 2010, 10:320
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without therapy; 7) preoperative chemotherapy influ-
ences the associations between HIF-1α and leptin in pri-
mary and metastatic tumors, HIF-1α and ObR in
metastatic tumors, HIF-1α and Glut-1 in primary tumors;
Glut-1 and ERβ in primary tumors; Glut-1 and Ki-67 in
primary and metastatic tumors.
Hypoxia in solid tumors is associated with the accumu-
lation of HIF-1α and activation of HIF-1-dependent tran-
scription of genes regulating cell motility, invasion, and
angiogenesis [14,41]. Bos et al. (2001, 2003) reported that
HIF-1α overexpression was associated with more aggres-
sive breast cancer. We speculate that HIF-1 could also
improve glucose consumption in hypoxic cancer cells by
the stimulation of glucose transporter Glut-1 expression
[12,42]. Our results suggest that hypoxic conditions
resulted in coordinated upregulation of HIF-1α and Glut-
1 in primary tumors. It is consistent with results of Li et
al. (2006) who showed that knockdown of HIF-1α in
MCF-7 breast cancer cells attenuated the expression of
Glut-1 mRNA and other genes [43]. Additionally, the
HIF-1α knockdown cells displayed increased sensitivity
to chemotherapeutic agents [43]. Interestingly, we noted
that the association between HIF-1α and Glut-1 was lost
in lymph node metastases as well as in tumors after pre-
operative chemotherapy. Potentially, this could be related
to downregulation of HIF-1 coregulators, such as p300
[44], due to neoadjuvant therapy or genetic rearrange-
ments in metastatic cells [45], which could result in defi-
cient Glut-1 gene transcription [46,47].
The associations between HIF-1α and the leptin system
identified by us in this study confirm the results obtained
by Cascio et al. (2008), Bartella et al. (2008) and Garofalo
et al. (2006) who demonstrated that physiologic hypoxia
and/or accumulation of HIF-1α due to hypoxia-mimick-
ing conditions or stabilization of HIF-1a by growth fac-
tors can stimulate leptin and/or ObR expression in breast
cancer cells [34,36,37].
According to our knowledge, the present analysis is the
first to reveal a positive correlation between HIF-1α and
leptin, as well as between HIF-1α and ObR not only in
primary tumors, but also in metastasis [31,33,34,36-38].
We reported analogous associations in human colorectal
Table 3: Correlation between HIF-1α, GLUT-1 and other studied biomarkers in primary breast cancer in patients without and after 
preoperative chemotherapy.
Compared 
biomarkers
Primary tumors without preoperative chemotherapy; 
n = 71
Primary tumors after preoperative chemotherapy; n = 45
prP r
HIF-1α - Ob <0.0001 0.532 0.116 0.288
HIF-1α - ObR 0.002 0.319 0.007 0.445
HIF-1α - ERα 0.055 -0.194 0.244 0.191
HIF-1α - ERβ 0.002 0.408 0.031 0.346
HIF-1α - Ki-67 0.822 -0.031 0.801 0.042
HIF-1α -GLUT-1 0.02 0.437 0.625 -0.087
GLUT-1 - Ob 0.930 0.018 0.431 0.152
GLUT-1 - ObR 0.472 0.139 0.338 -0.165
GLUT-1 - ERα 0.022 -0.410 0.038 -0.337
GLUT-1 - ERβ 0.008 0.467 0.281 0.179
GLUT-1 - Ki-67 0.017 0.433 0.050 0.320
n - number of studied cases.Koda et al. BMC Cancer 2010, 10:320
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cancer [30]. Cumulatively, present and previous data sug-
gest the involvement of tissue hypoxia in the stimulation
of leptin and ObR expression in human cancers
[28,30,34]. The overexpression of the leptin system could
lead to leptin-enhanced tumor growth and progression
under hypoxic conditions.
One of the features of breast cancer progression is the
development of resistance to hormonal therapy. The pos-
sible mechanism of this phenomenon could be related to
differential ER expression in metastatic and primary sites,
as described by us before [40]. Our present study suggests
that tumor malignancy might correlate with loss of ERα
expression. Indeed, hypoxia could induce ERα downregu-
lation via proteasome-dependent pathway [48,49]. Cho et
al. (2005) suggested that ERα downregulation under
hypoxic conditions in human breast cancer involves pro-
tein interactions between ERα and HIF-1α [50].
Negative correlation between Glut-1 and ERα found in
this study suggests that loss of ERα in breast cancer is
associated with overexpression of Glut-1, which could
facilitate proliferation, survival and possibly progression
and dedifferentiation of cancer cells [51,52].
I n  c o n t r a s t  t o  E R α ,  w e  n o t e d  a  p o s i t i v e  c o r r e l a t i o n
between ERβ and hypoxia markers HIF-1α, Glut-1. Our
observations are consistent with results of Cordadini et
al. (2004), who reported that hypoxic conditions upregu-
lated ERβ protein levels in breast cancer cells [53]. More-
over, sequence analysis of the ERβ promoter region
contains specific sequence for HRE, which might explain
coexpression of ERβ and HIF-1α.
Although preoperative chemotherapy is an integral part
of management of patients with advanced breast cancer,
its impact on cancer biomarkers and their interrelation-
ships in primary and metastatic tumors is poorly recog-
nized. Our study clearly suggest that preoperative
chemotherapy alters the expression of and relationships
among several hypoxia-related proteins, specifically, HIF-
1α and leptin in primary and metastatic tumors, HIF-1α
and ObR in metastatic tumors, HIF-1α and Glut-1 in pri-
mary tumors; Glut-1 and ERβ in primary tumors; Glut-1
and Ki-67 in primary and metastatic tumors. These data
Table 4: Correlation between HIF-1α, GLUT-1 and other studied biomarkers in lymph node metastases in patients without and after 
preoperative chemotherapy.
Compared biomarkers Lymph node metastases without preoperative 
chemotherapy; n = 35
Lymph node metastases after preoperative 
chemotherapy; n = 30
Pr p r
HIF-1α - Ob 0.013 0.533 0.465 0.168
HIF-1α - ObR 0.083 0.387 0.150 0.302
HIF-1α - ERα 0.133 -0.327 0.908 0.024
HIF-1α - ERβ 0.119 0.474 0.188 0.272
HIF-1α - Ki-67 0.604 -0.167 0.951 -0.013
HIF-1α -GLUT-1 0.776 -0.177 0.401 -0.198
GLUT-1 - Ob 0.405 0.242 0.361 -0.209
GLUT-1 - ObR 0.261 -0.309 0.335 -0.216
GLUT-1 - ERα 0.017 -0.606 0.021 -0.469
GLUT-1 - ERβ 0.677 -0.117 0.785 0.059
GLUT-1 - Ki-67 0.078 0.468 0.749 0.069
n - number of studied cases.Koda et al. BMC Cancer 2010, 10:320
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are reminiscent of previous observations pointing to dif-
ferential expression of ERα, ERβ and Ki-67 expression in
metastatic breast cancer versus primary cancer, and sig-
nificant influence of preoperative chemotherapy on these
biomarkers [40,43,54-56].
Conclusions
In conclusion, our results suggest that breast tumor cells
experience hypoxic conditions, as indicated by the
expression of such markers as HIF-1α, Glut-1, leptin and
ObR. Interestingly, the relationships among these pro-
teins differ in primary and metastatic tumors and might
be influenced by preoperative chemotherapy. Thus, anal-
ysis of biomarkers in both primary and metastatic tumors
before and after chemotherapy could help in understand-
ing the mechanisms of breast cancer progression and
select the optimal individualized treatment options.
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